## The impact of CF-M801 osteoblasts derived from human umbilical cord stroma cells, on bone regeneration in a goat femur partial defect model

Sunray Lee<sup>1</sup>, Yeon Kyung Lee<sup>1</sup>, Myoung Hwan Kim<sup>2</sup>, Ha Jin Kim<sup>1</sup>, Ji Yeon Mun<sup>1</sup>, Ah-Reum Kwon<sup>1</sup>, Bum-jin Shim<sup>3</sup>, Seung-Hoon Baek<sup>3</sup>, Shin-Yoon Kim<sup>4</sup>, Hyun Sook Park<sup>1</sup>

<sup>1</sup> CEFO Co., Ltd, 45-13 Ujeongguk-ro Jongno-Gu, Seoul 03150, South Korea

<sup>2</sup>ENDIC Co., Ltd, 212-9 Opo-ro, Opo-eup, Gwangju, Gyeonggi-do, South Korea

<sup>3</sup>Department of Orthopedic Surgery, Kyungpook National University Hospital, Kyungpook National University, College of Medincine, Daegu 41944, South Korea

Email of Presenting Author: Hyun Sook Park, hspark@cefobio.com

**OBJECTIVES**: This study aimed to assess whether the transplantation of CF-M801 osteoblasts enhances bone regeneration in a goat femur partial defect model.

## METHODS:

**Experimental Setup:** Adult goats with open femur partial fractures were utilized, involving the removal of a circular bone segment measuring 0.8 cm to create the partial defect.

Osteoblast Preparation: CF-M801 osteoblasts were derived from human umbilical cord stroma cells and were characterized for their osteogenic properties using various markers including alkaline phosphatase activity, alizarin-red staining, and expression of matrix proteins such as type 1 collagen, osteopontin, and osteocalcin.

**Treatment Groups**: Alginate capsules were produced using 3D printing and transplanted into the bone defects either with CF-M801 osteoblasts or without (control).

Evaluation: Bone regeneration progress was assessed at 13 and 26 weeks after inducing the bone defects.

- Micro-CT and Histology: Micro-CT scans and histological analysis were conducted to evaluate bone formation and scaffold degradation.
- Tissue Staining: Hematoxylin and eosin (H&E) staining and Masson's Trichrome staining were used to visualize tissue characteristics and new bone formation.

## **RESULTS:**

Micro-CT Measurements: The micro-CT measurements did not reveal a significant difference in bone formation between the groups with and without CF0M801 osteoblasts.

**Alginate Scaffold Degradation**: Microscopic analysis indicated that the group transplanted with CF-M801 osteoblasts significantly enhanced new bone formation between the 13<sup>th</sup> and 26<sup>th</sup> weeks post-injury.

**CONCLUSION:** The study's findings suggest that the transplantation of CF-M801 osteoblasts derived from human umbilical cord stroma cells has the potential to enhance bone regeneration in a goat femur partial defect model. Although micro-CT measurements did not display significant differences, microscopic analysis highlighted the crucial role of CF-M801 osteoblasts in a scaffold degradation and new bone formation. This research underscores the potential of osteoblast-based cell therapy as a strategy to promote bone repair and regeneration.

**ACKNOWLEDGEMENTS:** This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: 22D0801L1 & 22C0604L1)

